Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Skip Nav Destination April 27, 2022 The extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered after three to...

  • 1528738342547898369 Profile photo of Madelyn

    The extension of #caplacizumab application intervals from daily to alternate-day dosing may be safely considered after three to four weeks in select patients with #iTTP and offers cost-saving benefits and more individualized therapy https://t.co/6yKVV0KCv4 - view on twitter

Skip Nav Destination April 27, 2022 The anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was effective and had an acceptable safety profile in...

Blood Podcast – Season 3, Episode 20 | Blood | American Society of Hematology HLA-DQ heterodimers and transplantation, the genomic landscape of LGL leukemia, and an...

Skip Nav Destination April 27, 2022 A new risk model was found to predict grade 4 bleeding in patients with acute myeloid leukemia (AML)...

Two recent studies explored the activity and safety profile of a combination treatment of ibrutinib and rituximab in patients with previously untreated mantle cell...

For hematologists looking to continue their medical education, maintain certifications, or simply sharpen their skills, ASH Academy On Demand offers a wide range of...

Skip Nav Destination April 27, 2022 Vaccine-induced immune thrombotic thrombocytopenia (VITT), a potentially fatal syndrome characterized by aggressive thrombosis, has recently been linked to...

Read Volume 2020 Issue 1 of Hematology, ASH Education...

Read the current issue of...

Skip Nav Destination April 27, 2022 Survivors of hematologic malignances were found to have disproportionately greater insulin resistance with increasing body mass index (BMI)...